MediWound Ltd.
MDWD
$-0.47
Change (1 day)
$24.00
Year High
$7.45
Year Low
Categories
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd. (MDWD) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 4.42 M | -5,322,000 | 27.19 M | 66.46 M | 49.7 M |
| 2022 | 9.53 M | -33,049,000 | 39.1 M | 50.02 M | 45.84 M |
| 2021 | 2.71 M | -9,655,000 | 24.33 M | 19.74 M | 14.95 M |
| 2020 | 3.23 M | -15,635,000 | 23.8 M | 31.07 M | 26.19 M |
| 2019 | 4.55 M | -5,236,000 | 25.42 M | 40.59 M | 35.62 M |